Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 95

1.

Broad phenotypic changes associated with gain of radiation resistance in head and neck squamous cell cancer.

Bansal N, Mims J, Kuremsky JG, Olex AL, Zhao W, Yin L, Wani R, Qian J, Center B, Marrs GS, Porosnicu M, Fetrow JS, Tsang AW, Furdui CM.

Antioxid Redox Signal. 2014 Jul 10;21(2):221-36. doi: 10.1089/ars.2013.5690. Epub 2014 Apr 10.

PMID:
24597745
[PubMed - in process]
Free PMC Article
2.

Snail controls the mesenchymal phenotype and drives erlotinib resistance in oral epithelial and head and neck squamous cell carcinoma cells.

Dennis M, Wang G, Luo J, Lin Y, Dohadwala M, Abemayor E, Elashoff DA, Sharma S, Dubinett SM, St John MA.

Otolaryngol Head Neck Surg. 2012 Oct;147(4):726-32. Epub 2012 May 7.

PMID:
22568942
[PubMed - indexed for MEDLINE]
3.

Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation.

Harari PM, Huang SM.

Int J Radiat Oncol Biol Phys. 2001 Feb 1;49(2):427-33.

PMID:
11173137
[PubMed - indexed for MEDLINE]
4.

Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma.

Frederick BA, Helfrich BA, Coldren CD, Zheng D, Chan D, Bunn PA Jr, Raben D.

Mol Cancer Ther. 2007 Jun;6(6):1683-91. Epub 2007 May 31.

PMID:
17541031
[PubMed - indexed for MEDLINE]
Free Article
5.

Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.

Benavente S, Huang S, Armstrong EA, Chi A, Hsu KT, Wheeler DL, Harari PM.

Clin Cancer Res. 2009 Mar 1;15(5):1585-92. doi: 10.1158/1078-0432.CCR-08-2068. Epub 2009 Feb 3.

PMID:
19190133
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib.

Giles KM, Kalinowski FC, Candy PA, Epis MR, Zhang PM, Redfern AD, Stuart LM, Goodall GJ, Leedman PJ.

Mol Cancer Ther. 2013 Nov;12(11):2541-58. doi: 10.1158/1535-7163.MCT-13-0170. Epub 2013 Sep 11.

PMID:
24026012
[PubMed - indexed for MEDLINE]
7.

Radioresistant head and neck squamous cell carcinoma cells: intracellular signaling, putative biomarkers for tumor recurrences and possible therapeutic targets.

Skvortsov S, Jimenez CR, Knol JC, Eichberger P, Schiestl B, Debbage P, Skvortsova I, Lukas P.

Radiother Oncol. 2011 Oct;101(1):177-82. doi: 10.1016/j.radonc.2011.05.067. Epub 2011 Jun 21.

PMID:
21700351
[PubMed - indexed for MEDLINE]
9.

Grape seed proanthocyanidins inhibit the invasive potential of head and neck cutaneous squamous cell carcinoma cells by targeting EGFR expression and epithelial-to-mesenchymal transition.

Sun Q, Prasad R, Rosenthal E, Katiyar SK.

BMC Complement Altern Med. 2011 Dec 21;11:134. doi: 10.1186/1472-6882-11-134.

PMID:
22188922
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.

Quesnelle KM, Wheeler SE, Ratay MK, Grandis JR.

Cancer Biol Ther. 2012 Aug;13(10):935-45. doi: 10.4161/cbt.20846. Epub 2012 Aug 1.

PMID:
22785204
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer.

Keysar SB, Le PN, Anderson RT, Morton JJ, Bowles DW, Paylor JJ, Vogler BW, Thorburn J, Fernandez P, Glogowska MJ, Takimoto SM, Sehrt DB, Gan GN, Eagles-Soukup JR, Serracino H, Hirsch FR, Lucia MS, Thorburn A, Song JI, Wang XJ, Jimeno A.

Cancer Res. 2013 Jun 1;73(11):3381-92. doi: 10.1158/0008-5472.CAN-12-4047. Epub 2013 Apr 10.

PMID:
23576557
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.

Hah JH, Zhao M, Pickering CR, Frederick MJ, Andrews GA, Jasser SA, Fooshee DR, Milas ZL, Galer C, Sano D, William WN Jr, Kim E, Heymach J, Byers LA, Papadimitrakopoulou V, Myers JN.

Head Neck. 2013 Sep 30. doi: 10.1002/hed.23499. [Epub ahead of print]

PMID:
24123531
[PubMed - as supplied by publisher]
13.

Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).

Cohen RB.

Cancer Treat Rev. 2014 May;40(4):567-77. doi: 10.1016/j.ctrv.2013.10.002. Epub 2013 Oct 12. Review.

PMID:
24216225
[PubMed - indexed for MEDLINE]
14.

Apricoxib upregulates 15-PGDH and PGT in tobacco-related epithelial malignancies.

St John MA, Wang G, Luo J, Dohadwala M, Hu D, Lin Y, Dennis M, Lee JM, Elashoff D, Lawhon T, Zaknoen SL, Burrows FJ, Dubinett SM.

Br J Cancer. 2012 Aug 7;107(4):707-12. doi: 10.1038/bjc.2012.203. Epub 2012 Jul 24.

PMID:
22828609
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Epithelial-to-mesenchymal transition and c-myc expression are the determinants of cetuximab-induced enhancement of squamous cell carcinoma radioresponse.

Skvortsova I, Skvortsov S, Raju U, Stasyk T, Riesterer O, Schottdorf EM, Popper BA, Schiestl B, Eichberger P, Debbage P, Neher A, Bonn GK, Huber LA, Milas L, Lukas P.

Radiother Oncol. 2010 Jul;96(1):108-15. doi: 10.1016/j.radonc.2010.04.017. Epub 2010 May 5.

PMID:
20451273
[PubMed - indexed for MEDLINE]
16.

Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.

Erjala K, Sundvall M, Junttila TT, Zhang N, Savisalo M, Mali P, Kulmala J, Pulkkinen J, Grenman R, Elenius K.

Clin Cancer Res. 2006 Jul 1;12(13):4103-11.

PMID:
16818711
[PubMed - indexed for MEDLINE]
Free Article
17.

Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.

Suda K, Tomizawa K, Fujii M, Murakami H, Osada H, Maehara Y, Yatabe Y, Sekido Y, Mitsudomi T.

J Thorac Oncol. 2011 Jul;6(7):1152-61. doi: 10.1097/JTO.0b013e318216ee52.

PMID:
21597390
[PubMed - indexed for MEDLINE]
18.

A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma.

Box C, Mendiola M, Gowan S, Box GM, Valenti M, Brandon Ade H, Al-Lazikani B, Rogers SJ, Wilkins A, Harrington KJ, Eccles SA.

Eur J Cancer. 2013 Jul;49(11):2512-21. doi: 10.1016/j.ejca.2013.03.011. Epub 2013 Apr 10.

PMID:
23582742
[PubMed - indexed for MEDLINE]
19.

Cisplatin and radiation sensitivity in human head and neck squamous carcinomas are independently modulated by glutathione and transcription factor NF-kappaB.

Kato T, Duffey DC, Ondrey FG, Dong G, Chen Z, Cook JA, Mitchell JB, Van Waes C.

Head Neck. 2000 Dec;22(8):748-59.

PMID:
11084634
[PubMed - indexed for MEDLINE]
20.

The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.

Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, Yala S, Kanteti R, Cohen EE, Lingen MW, Martin L, Krishnaswamy S, Klein-Szanto A, Christensen JG, Vokes EE, Salgia R.

Cancer Res. 2009 Apr 1;69(7):3021-31. doi: 10.1158/0008-5472.CAN-08-2881. Epub 2009 Mar 24.

PMID:
19318576
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk